Automate Your Wheel Strategy on GILD
With Tiblio's Option Bot, you can configure your own wheel strategy including GILD - and automate your put writes, covered calls, and full wheel strategy. Just connect one of the supported brokerages: tastytrade, Schwab, TradeStation or Tradier and go.
Start Your Free Trial NowKey Metrics & Ratings
- symbol GILD
- Rev/Share 23.3998
- Book/Share 17.2607
- PB 6.8812
- Debt/Equity 0.1308
- CurrentRatio 1.5316
- ROIC 0.2092
- MktCap 147367925620.0
- FreeCF/Share 7.6589
- PFCF 15.4798
- PE 18.2051
- Debt/Assets 0.0479
- DivYield 0.0266
- ROE 0.4074
- Rating A-
- Score 4
- Recommendation Buy
- P/E Score 2
- DCF Score 5
- P/B Score 1
- D/E Score 2
Recent Analyst Ratings
| Type | Ticker | Analyst Firm | Previous Rating | Current Rating | Previous Price Target | Current Price Target | Date |
|---|---|---|---|---|---|---|---|
| Resumed | GILD | Truist | -- | Buy | -- | $140 | Nov. 24, 2025 |
| Initiation | GILD | Scotiabank | -- | Sector Outperform | -- | $140 | Nov. 13, 2025 |
| Upgrade | GILD | Daiwa Securities | Neutral | Outperform | -- | $128 | Aug. 19, 2025 |
| Upgrade | GILD | Truist | Hold | Buy | -- | $127 | Aug. 8, 2025 |
| Upgrade | GILD | Needham | Hold | Buy | -- | $133 | July 25, 2025 |
| Resumed | GILD | Cantor Fitzgerald | -- | Overweight | -- | $125 | April 22, 2025 |
| Reiterated | GILD | Oppenheimer | -- | Outperform | $115 | $132 | March 4, 2025 |
| Upgrade | GILD | Deutsche Bank | Hold | Buy | -- | $120 | Feb. 18, 2025 |
| Upgrade | GILD | DZ Bank | Hold | Buy | -- | $108 | Feb. 13, 2025 |
| Upgrade | GILD | Morgan Stanley | Equal Weight | Overweight | $87 | $113 | Jan. 10, 2025 |
News
GILD's Bictegravir and Lenacapavir Regimen for HIV Meets Primary Goal
Published: December 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead said its once-daily bictegravir/lenacapavir tablet met non-inferiority vs Biktarvy in phase III ARTISTRY-2, paving the way for filings.
Read More
3 Companies Turning Big Cash Flow Into Bigger Shareholder Gains
Published: December 15, 2025 by: MarketBeat
Sentiment: Positive
Inflation, interest rates, and broader economic uncertainty have forced companies across many sectors to prioritize efficiency. In this environment, it can be particularly challenging for firms to maintain cash flow, which is vital to their continued healthy operations and growth.
Read More
Here's Why Gilead Sciences (GILD) is a Strong Value Stock
Published: December 11, 2025 by: Zacks Investment Research
Sentiment: Positive
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Read More
Investors Heavily Search Gilead Sciences, Inc. (GILD): Here is What You Need to Know
Published: December 04, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Read More
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
Published: December 03, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. (GILD) Presents at Evercore 8th Annual Healthcare Conference Transcript
Read More
Why Gilead Sciences (GILD) is a Top Momentum Stock for the Long-Term
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.
Read More
Bristol Myers vs Gilead Sciences: Which Biotech Stock Is a Better Bet Now?
Published: November 28, 2025 by: Zacks Investment Research
Sentiment: Positive
GILD's HIV strength, new approvals, and rising estimates set it apart as it edges past a challenged rival in growth prospects.
Read More
Why Gilead Sciences (GILD) is a Top Value Stock for the Long-Term
Published: November 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
Read More
Here is What to Know Beyond Why Gilead Sciences, Inc. (GILD) is a Trending Stock
Published: November 20, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead (GILD) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.
Read More
Gilead Sciences, Inc. (GILD) Presents at Jefferies London Healthcare Conference 2025 Transcript
Published: November 19, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. ( GILD ) Jefferies London Healthcare Conference 2025 November 19, 2025 9:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Amy Li - Jefferies LLC, Research Division Presentation Amy Li Jefferies LLC, Research Division Thanks so much for attending the Jefferies Healthcare -- London Healthcare Conference. It's already day 3.
Read More
Gilead Joins Partners for Delivery of First Shipments of Breakthrough Twice-yearly Lenacapavir for HIV Prevention to Sub-Saharan Africa
Published: November 18, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif. & MBABANE, Eswatini--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) today announced the delivery of first shipments of lenacapavir – Gilead's twice-yearly injectable HIV-1 capsid inhibitor – for the prevention of HIV as pre-exposure prophylaxis (PrEP) to Eswatini and Zambia. The deliveries advance ongoing efforts to accelerate equitable access to long-acting HIV prevention options across sub-Saharan Africa, which is home to approximately two-thirds of all people livin.
Read More
GILD's Investigational Regimen for HIV Treatment Meets Primary Goal
Published: November 14, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead's ARTISTRY-1 success boosts shares as its once-daily bictegravir/lenacapavir combo proves non-inferior to complex regimens.
Read More
Gilead Sciences, Inc. (GILD) Presents at UBS Global Healthcare Conference 2025 Transcript
Published: November 10, 2025 by: Seeking Alpha
Sentiment: Neutral
Gilead Sciences, Inc. ( GILD ) UBS Global Healthcare Conference 2025 November 10, 2025 11:00 AM EST Company Participants Andrew Dickinson - Chief Financial Officer Presentation Unknown Analyst Good morning, everyone. My name is [ Dina Elmonshed.
Read More
Is Trending Stock Gilead Sciences, Inc. (GILD) a Buy Now?
Published: November 05, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
HIV, Livdelzi Fuel GILD's Q3 Top Line Amid Cell Therapy Sales Decline
Published: November 04, 2025 by: Zacks Investment Research
Sentiment: Negative
Gilead Sciences' HIV therapies and liver drug Livdelzi drive Q3 revenue growth, offsetting weaker Veklury and Cell Therapy sales.
Read More
Gilead and Kite Showcase Continued Progress in Transforming Blood Cancer Care With New Cell Therapy Data at ASH 2025
Published: November 03, 2025 by: Business Wire
Sentiment: Neutral
FOSTER CITY, Calif.--(BUSINESS WIRE)--Gilead Sciences, Inc. (Nasdaq: GILD) and Kite, a Gilead Company, will present 21 abstracts, including 5 oral presentations, during the 67th American Society of Hematology (ASH) Annual Meeting and Exposition (December 6-9). These data showcase Kite's continued progress in transforming blood cancer care and expanding the reach and impact of CAR T-cell therapy. “Kite is dedicated to advancing cell therapy as a path to cures, and our data at ASH will reflect me.
Read More
Gilead's HIV Drugs Power Earnings Beat, Company Eyes Multiple Launches By 2026
Published: October 31, 2025 by: Benzinga
Sentiment: Positive
Gilead Sciences Inc (NASDAQ:GILD) on Thursday reported adjusted earnings of $2.47 per share, beating the consensus of $2.13.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 31, 2025 by: Zacks Investment Research
Sentiment: Positive
The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.
Read More
Healthy Returns: What to expect from Eli Lilly, Merck, Gilead and AbbVie third-quarter earnings
Published: October 28, 2025 by: CNBC
Sentiment: Positive
Eli Lilly, Merck, Gilead, Bristol Myers Squibb and AbbVie, among other pharmaceutical companies, are slated to report third-quarter earnings this week.
Read More
What's in Store for These 5 Pharma Bigwigs This Earnings Season?
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Neutral
As earnings season accelerates, pharma heavyweights LLY, MRK, ABBV, BMY and GILD prepare to reveal their Q3 results amid a strong sector start.
Read More
Curious about Gilead (GILD) Q3 Performance? Explore Wall Street Estimates for Key Metrics
Published: October 27, 2025 by: Zacks Investment Research
Sentiment: Positive
Looking beyond Wall Street's top-and-bottom-line estimate forecasts for Gilead (GILD), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the quarter ended September 2025.
Read More
What To Expect From Gilead In Q3 2025
Published: October 24, 2025 by: Seeking Alpha
Sentiment: Positive
Here we are approaching an important event, namely October 30, when Gilead will announce its results for the third quarter of 2025. Since my last article, its stock price has hit new 52-week highs. On October 23, Gilead announced that it will announce data on the switching of people with PBC from obeticholic acid to its 'rising star' Livdelzi at The Liver Meeting 2025.
Read More
AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP
Published: October 21, 2025 by: Business Wire
Sentiment: Neutral
WASHINGTON--(BUSINESS WIRE)--AHF: 80 Organizations Denounce Gilead on Price Hikes Gutting ADAP.
Read More
Gilead Sciences, Inc. (GILD) is Attracting Investor Attention: Here is What You Should Know
Published: October 16, 2025 by: Zacks Investment Research
Sentiment: Positive
Zacks.com users have recently been watching Gilead (GILD) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Read More
Final Trades: Gilead, Rocket Lab, Palo Alto and Coinbase
Published: October 10, 2025 by: CNBC Television
Sentiment: Neutral
The Investment Committee give you their top stocks to watch for the second half.
Read More
These 2 Medical Stocks Could Beat Earnings: Why They Should Be on Your Radar
Published: October 08, 2025 by: Zacks Investment Research
Sentiment: Positive
Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.
Read More
Gilead Resolves Patent Litigations for HIV Treatment Biktarvy
Published: October 07, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead's settlement on Biktarvy patents delays generic entry until 2036, boosting investor confidence.
Read More
My Top 5 Biotech Stocks Big Pharma Could Buy Next
Published: October 06, 2025 by: Seeking Alpha
Sentiment: Positive
While AI hype reigns on Wall Street, the healthcare sector is still far from the peaks it reached during the COVID-19 pandemic. And what's more important, many of the biotech stocks remain outside of Mr. Market's interest zone. Since the exclusivity of key blockbusters of 'giants', including Merck and Pfizer, expires in the next 4 years, there is an urgent need to continue rejuvenating their portfolios of drugs.
Read More
Dividend Shields: Top 5 Income Stocks
Published: September 30, 2025 by: Seeking Alpha
Sentiment: Neutral
Market optimism has waned as investors weighed mixed data, Fed guidance, and sector-specific risks after the S&P 500 hit eight record highs in September. Strong GDP and jobs data have tempered rate cut expectations, resulting in a slight market pullback, though 89% of traders still predict an October rate reduction. Beyond shifting rate cut expectations, seasonal weakness, upcoming earnings, and concerns around stretched valuations could contribute to market volatility.
Read More
Gilead Sciences Surges 26.5% YTD: Buy, Sell or Hold the Stock?
Published: September 24, 2025 by: Zacks Investment Research
Sentiment: Positive
Gilead surges 26.5% YTD in 2025 as HIV franchise gains momentum with Yeztugo approval, offsetting cell therapy pressures.
Read More
About Gilead Sciences, Inc. (GILD)
- IPO Date 1992-01-22
- Website https://www.gilead.com
- Industry Drug Manufacturers - General
- CEO Daniel O'Day
- Employees 17600